Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | PRKCB | P05771 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424839 | 0.90 | PTPN1 (0.61) | PTPN1BRD4HTR7NPC1RAB9A | |
| SCHEMBL29221014 | 0.87 | PTPN1 (0.61) | PTPN1HTR7ASH1L | |
| SCHEMBL29221042 | 0.87 | PTPN1 (0.58) | PTPN1BRD4HTR7NPC1RAB9A | |
| SCHEMBL13302236 | 0.86 | HTR1A (0.55) | PTPN1HTR7MEN1KMT2AASH1L | |
| SCHEMBL16509551 | 0.86 | MEN1 (0.52) | PTPN1BRD4HTR7NPC1RAB9A | |
| SCHEMBL29221024 | 0.85 | PTPN1 (0.60) | PTPN1HTR7NPC1RAB9AKDM4E | |
| SCHEMBL29221058 | 0.85 | PTPN1 (0.60) | PTPN1HTR7PIM1 | |
| SCHEMBL29221047 | 0.84 | PTPN1 (0.62) | PTPN1HTR7 | |
| SCHEMBL5426730 | 0.84 | PTPN1 (0.54) | PTPN1HTR7KDM4EMAPTKMT2A | |
| SCHEMBL13302375 | 0.83 | PTPN1 (0.51) | PTPN1BRD4HTR7NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893576-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-03-05 | — | — | EP | claimed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | claimed |
| WO-2006125324-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-11-30 | — | — | WO | claimed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| EP-1893576-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-03-05 | — | — | EP | disclosed |
| US-20070015813-A1 | Treatment of protein folding disorders | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-01-18 | — | — | US | disclosed |
| WO-2006125324-A1 | TREATMENT OF PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | PTPN1 4116/4885BRD4 521/4885HTR7 2988/4885 |
| US-20070015813-A1 | Treatment of protein folding disorders | HSPA5, TTR, TUFM | PTPN1 4634/4885BRD4 509/4885HTR7 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.